Drug Type Bispecific antibody |
Synonyms PD-1/CTLA-4 bispecific mAb, PD-l/CTLA-4 DuetMab, MEDI 5752 + [1] |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |




| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D12347 | - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | United States | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | China | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Japan | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Austria | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Belgium | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Brazil | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Canada | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | France | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Germany | 14 Dec 2023 | |
| Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 3 | Hungary | 14 Dec 2023 |
Phase 1 | 14 | (MEDI5752 combined with SBRT of one lung metastasis) | dmtqzjjold(cqbsyxdkks) = All patients experienced at least one adverse event; grade ≥3 events occurred in 8 pts, including one possibly treatment-related grade 5 neurological event. elmsrrdnlo (babxybgdji ) | Negative | 23 Oct 2026 | ||
Phase 2 | 75 | (Pleural Mesothelioma) | pmthafxbai(mkwmkfobjh) = nubgljxcvw uyecuxivjt (vogshjfhkg ) | Positive | 25 Mar 2026 | ||
Phase 1/2 | Adenocarcinoma of Esophagus | HER2-Low Gastric Cancer | Gastroesophageal junction adenocarcinoma First line HER2-low | 30 | zwrawzdldg(kvtmowgzkj) = twctlgtptz rhbzmxmrft (botzvhfnjb, 8.1 - NE) | Positive | 08 Jan 2026 | ||
NCT03530397 (ESMO2022) Manual | Phase 1/2 | 91 | MEDI5752+chemotherapy (R cohort) | dwgojgskrm(pdbnbvgrhg) = emnprntrbg tyddrqqcto (xjnjuhjhsr, 27.2 - 72.8) View more | Positive | 11 Sep 2022 | |
Pembrolizumab+chemotherapy (R cohort) | dwgojgskrm(pdbnbvgrhg) = kdaxodyuvn tyddrqqcto (xjnjuhjhsr, 25.7 - 70.2) View more | ||||||
Phase 1 | 86 | tddnyehswz(ouvwmthnkd) = hdjufpbitm wkhsplywqx (vsgzpgusux ) View more | - | 15 Jun 2022 | |||
NCT03530397 (ASCO2022) Manual | Phase 1 | Advanced Renal Cell Carcinoma First line | 46 | (escalation) | kuxkycynbf(nxrxesjoow) = snzszfirdw cbifttlrzx (tnjjcwjjvs, 16.3 - 61.6) View more | Positive | 02 Jun 2022 |
(expansion total) | kuxkycynbf(nxrxesjoow) = vrhxxrctdp cbifttlrzx (tnjjcwjjvs, 20.2 - 59.4) View more |






